Technical Analysis for CBAY - CymaBay Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 1.75 5.42% 0.09
CBAY closed up 5.42 percent on Friday, December 6, 2019, on 1.55 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CBAY trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 5.42%
Wide Bands Range Expansion 5.42%
Oversold Stochastic Weakness 5.42%
Narrow Range Bar Range Contraction 6.06%
NR7 Range Contraction 6.06%
Older signals for CBAY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Medicine Chemistry Disorders Health Care Therapeutic Products Regulus Therapeutics Metabolic Diseases Ii Diabetes Gout

Is CBAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 14.0
52 Week Low 1.29
Average Volume 1,930,744
200-Day Moving Average 8.14
50-Day Moving Average 4.42
20-Day Moving Average 3.74
10-Day Moving Average 2.04
Average True Range 0.43
ADX 37.87
+DI 16.11
-DI 43.25
Chandelier Exit (Long, 3 ATRs ) 4.77
Chandelier Exit (Short, 3 ATRs ) 2.59
Upper Bollinger Band 7.55
Lower Bollinger Band -0.06
Percent B (%b) 0.24
BandWidth 203.32
MACD Line -0.97
MACD Signal Line -0.73
MACD Histogram -0.2416
Fundamentals Value
Market Cap 76.57 Million
Num Shares 43.8 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -1.64
Price-to-Sales 82.44
Price-to-Book 122.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.95
Resistance 3 (R3) 1.94 1.86 1.92
Resistance 2 (R2) 1.86 1.81 1.87 1.91
Resistance 1 (R1) 1.81 1.78 1.83 1.82 1.90
Pivot Point 1.73 1.73 1.74 1.73 1.73
Support 1 (S1) 1.67 1.67 1.70 1.68 1.60
Support 2 (S2) 1.59 1.64 1.60 1.59
Support 3 (S3) 1.54 1.59 1.58
Support 4 (S4) 1.55